The foundation role of beta blockers across the cardiovascular disease spectrum: a year 2009 update.
Black
Henry R
HR
New York University Medical Center, New York, NY, USA. hrbmd63@gmail.com
Greenberg
Barry H
BH
Weber
Michael A
MA
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001578:Benzopyrans / Q000627:therapeutic use; D002227:Carbazoles / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000517:prevention & control; D000077261:Carvedilol; D004983:Ethanolamines / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D009203:Myocardial Infarction / Q000517:prevention & control; D000068577:Nebivolol; D011412:Propanolamines / Q000627:therapeutic use; D020521:Stroke / Q000517:prevention & control
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D001578:Benzopyrans; D002227:Carbazoles; D004983:Ethanolamines; D011412:Propanolamines; D000068577:Nebivolol; D000077261:Carvedilol